Evidence map›Paper›PMID 42539872›Full record

ArticleTherapeutic advances in neurological disorders2026

Impact of tobacco and alcohol consumption on disease progression and MRI in people with multiple sclerosis: results of the prospective cohort study NationMS.

Alex Maximilian Keller, Annika Möhl, Anke Salmen, Ralf Gold, Pia Renk, Luisa Klotz, Stefan Bittner, Vinzenz Fleischer, Friedemann Paul, Klemens Ruprecht and 11 more

Abstract read
In one paragraph

Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Alex Maximilian KellerInstitute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg DE-20246, Germany.ORCID https://orcid.org/0000-0002-0484-1718
Annika MöhlUniversity Medical Center Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany.
Anke SalmenDepartment of Neurology, Ruhr-Universität Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0002-4751-299X
Ralf GoldDepartment of Neurology, Ruhr-Universität Bochum, Bochum, Germany.
Pia RenkDepartment of Neurology, Ruhr-Universität Bochum, Bochum, Germany.
Luisa KlotzDepartment of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital Münster, Münster, Germany.ORCID https://orcid.org/0000-0001-5439-9633
Stefan BittnerDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), Johannes Gutenberg University Hospital Mainz, Mainz, Germany.ORCID https://orcid.org/0000-0003-2179-3655
Vinzenz FleischerDepartment of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn).ORCID https://orcid.org/0000-0002-3293-5121
Friedemann PaulDepartment of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
Klemens RuprechtDivision of Neuroimmunology, Department of Neurology, Heidelberg University, Heidelberg, Germany.
Katrin GiglhuberDepartment of Neurology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Hayrettin TumaniDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0002-1647-6201
Gisela AntonyCentral Information Office German Competence Network of Multiple Sclerosis, CIO Marburg GmbH, Lohra, Germany.
Uwe ZettlNeuroimmunological Section, Department of Neurology, University of Rostock, Rostock, Germany.
Sven G MeuthDepartment of Neurology, Heinrich-Heine-Universität Düsseldorf Medizinische Fakultät, Dusseldorf, Nordrhein-Westfalen, Germany.
Antonios BayasDepartment of Neurology, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany.ORCID https://orcid.org/0000-0002-7418-9040
Corinna TrebstDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Brigitte WildemannMolecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Florian Then BerghDepartment of Neurology, Leipzig University, Leipzig, Germany.
Daniel KotzAddiction Research and Clinical Epidemiology Unit, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Institute of General Practice, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Christoph HeesenInstitut für Neuroimmunologie und Multiple Sklerose, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0001-8131-9467

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lifestyle factors, such as smoking cigarettes and alcohol consumption, can influence disease progression in Multiple Sclerosis (MS). Objective: This study aimed to investigate the associations of smoking cigarettes and alcohol consumption with clinical parameters in people with MS (pwMS). Design: This is a prospective cohort study, analysing data from the German NationMS cohort. Methods: We analysed data of 1374 patients recruited between 2010 and 2017. Main outcomes were Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW) and Paced Auditory Serial Addition Test (PASAT). Secondary outcomes were number of T2 and GD+ lesions. We conducted logistic and linear mixed model regression, adjusted for age, sex, educational level, MS subtype. Results: Smoking cigarettes was associated with increased odds of reaching pre-defined cut-off values for EDSS and T25FW, as well as with increased mean differences across follow-ups. Alcohol consumption was associated with decreased odds of reaching the cut-off for EDSS and T25FW. Findings for PASAT were less consistent. We found no significant associations for T2 and GD+ lesions. Conclusion: This study provides further evidence that smoking cigarettes accelerates MS progression and that pwMS should be advised to quit smoking. However, this negative impact could not be demonstrated for alcohol consumption. Reverse causation cannot be ruled out and further research in this area is warranted. Trial registration: Instead of registration in a primary trial registry, a comprehensive study protocol was published a priori and is available online: https://osf.io/3xscy.

Indexed as

alcohol consumptiondisease progressionmultiple sclerosisprospective cohort studysmoking

Identifiers

PMID42539872
PMCPMC13424504

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.